Loading
Life sciences · Journal article
Communications Biology · October 27, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Adipose tissue expansion in obesity frequently outpaces vascularization, triggering hypoxia, fibrosis, and metabolic dysfunction. The molecular mechanisms coordinating adaptive angiogenesis during this expansion remain poorly understood. Here, we demonstrate that myeloid deletion of Transcription Factor EB ( Tfeb ) in high-fat diet-fed mice exacerbates epididymal white adipose tissue (eWAT) dysfunction, manifesting as profound hypoxia, fibrosis, and systemic insulin resistance. Mechanistically, single-cell RNA sequencing and chromatin immunoprecipitation assays reveal a novel TFEB-VEGFA axis: TFEB directly activates Vegfa transcription in macrophages, and its absence impairs angiogenic compensation under hypoxic stress. To translate these findings, we established an AI-driven, high-content screening platform to quantify TFEB nuclear translocation. We identified and validated Tetrandrine and Pacritinib as potent TFEB agonists. Notably, Tetrandrine acts via an mTOR-independent mechanism. Pharmacological activation of TFEB with these compounds restored adipose angiogenesis, resolved fibrosis, and improved insulin sensitivity in obese mice. These findings establish macrophage TFEB as a critical regulator of healthy adipose remodeling and validate the TFEB-VEGFA axis as a therapeutic target for metabolic diseases.